Medical devices & pharma

Chargeback & Contract Management for Medical and Pharmaceutical Distribution

You sell at a price a GPO negotiated, to a member you did not enrol, and recover the difference from a manufacturer who checks both.

Book a demo All of distributors

You are reading the distributor view of medical devices & pharma. The same sector looks different from the other side of the invoice.

Manufacturers view →

Eligibility is the entire control

A chargeback is valid only if that provider was entitled to that price on that date. Membership is effective-dated, which is why the check is so often skipped.

  • You
  • Channel partner
  • End customer
  • Your ledger
  • Value escapes here
  1. 1 Channel partner

    GPO contract price agreed

    Versioned by item and tier

  2. 2 End customer

    Wholesaler sells to provider

    At the contract price

  3. 3 Channel partner

    867 sell-through reported

    On the wholesaler’s cadence

    A missing 867 period fails silently

    silent gap in the basis

  4. 4 Channel partner

    Chargeback claimed (844)

  5. 5 You

    Eligibility checked

    As of the SALE date, not today

    Checked against a current roster, not history

    30–60% unvalidated

  6. 6 Your ledger

    Admin fee calculated

    On the same sales basis

    An invalid chargeback carries a fee on top of it

    the error compounds

Closed: Membership, contracts and prices held as effective-dated history, so every line is judged against the world as it was on the sale date.

Two readings of the same problem

If you own the P&L, the left column is your version. If you own the systems, the right column is yours. Both have to be true for the fix to work.

The financial problem

Every chargeback rejection is margin you already gave away at the point of sale.

  • You ship at the contract price immediately and claim the difference from the manufacturer afterwards. The discount is certain; the recovery is not.
  • Chargebacks are rejected on membership eligibility more than on price — the member was not on the roster on the date of sale, or was enrolled under a different identifier.
  • Rebills and resubmissions carry an administrative cost that frequently exceeds the value of the smaller lines, so those lines are written off as a matter of routine.
  • Contract price changes are effective-dated by the manufacturer and communicated late, so sales continue at a superseded price that will not be honoured.

The technical problem

Eligibility lives in a roster, price lives in a contract, and the sale happens before either is checked.

  • GPO membership rosters arrive periodically and are already stale; eligibility on the date of sale is what the manufacturer adjudicates against, not eligibility today.
  • The same hospital appears under a DEA number, an HIN, a GPO member ID and your own account code, and the chargeback must carry the one the manufacturer recognises.
  • Contract price files from hundreds of manufacturers arrive in different formats with different effective-date conventions.
  • Rejection reason codes are not standardised across manufacturers, so a single triage process cannot be built against them.

Benchmarks

What good looks like in medical devices & pharma

The numbers a well-run programme in this sector achieves. Treat any row you cannot answer as the finding.

Medical devices & pharma benchmarks
Metric Typical today Target
Chargebacks accepted on first submission 85 – 94% >99%
Rejections resolved rather than written off 50 – 70% >95%
Member eligibility verified as at date of sale spot-checked 100%, pre-invoice
Contract price changes applied by effective date 70 – 88% >99%
Days from sale to chargeback settled 20 – 45 days <10 days
Ranges are indicative benchmarks drawn from published channel-incentive and pricing research together with our own implementation experience. They vary widely by programme complexity, channel depth and data quality — treat them as the opening question in a diagnostic, not a guarantee.

The discount is immediate; the recovery is conditional

This is the structural asymmetry of pharmaceutical and med-surg distribution. You give the discount at the moment of sale and ask for it back afterwards. If the chargeback is rejected the sale still happened, at a price that no longer makes sense.

Which means the control has to move earlier. Validating price and eligibility before the invoice goes out is the difference between a chargeback operation and a collections operation.

Eligibility, not price, is what fails

Most people assume chargeback rejections are pricing disputes. They are usually not. They are membership problems — the facility was not on the roster on the date of sale, or was enrolled under an identifier the manufacturer does not map to yours. Rosters are periodic and always slightly stale, and adjudication is against eligibility as at the sale date, not as at today.

Holding roster history with as-at dates, and resolving facility identity across DEA, HIN, GPO member ID and your own account code, is what moves first-pass acceptance from the low nineties to essentially all of it.

What good looks like

  • First-submission acceptance above 99%. In a high-volume chargeback business, every point below that is a queue of people fixing things by hand.
  • Above 95% of rejections resolved — small lines only get worked when triage is automatic.
  • Eligibility verified pre-invoice, 100% — the only place the check is actually cheap.

How RevUpra runs this

Contract prices and membership rosters are held with effective dates and full history, so eligibility is evaluated as at the date of sale rather than as at now. Facility identity is cross-referenced across every identifier scheme in play, which is what lets the chargeback carry the one each manufacturer recognises. Claims are generated from validated lines, rejections are normalised into a single triage queue regardless of each manufacturer’s reason codes, and the whole flow settles against locked periods so the recovery you accrued is the recovery you book.

Leak points

Where the money goes in this sector

The points from our nine-point taxonomy that bite hardest in this sector, numbered as they are everywhere else on the site so you can compare one sector against another.

02

Contract drift

“You are operating a version of the deal nobody signed.”

Typical cost
0.5% – 2.0% of contracted revenue
Benchmark
Best practice is zero drift — every executed term traceable to the clause that created it.

How it closes: The contract is the front door. Terms are mashed live from the deal, redlined with attribution, executed, and the executed version is what the engine runs.

See the module →
03

Identifier mismatch

“The match failed, so the money did not move.”

Typical cost
0.4% – 1.5% of rebate-eligible revenue
Benchmark
Mature programmes hold unmatched transaction volume under 0.5% after cross-reference.

How it closes: A cross-reference engine reconciles partner, product and entity identifiers automatically, and every unmatched row is surfaced as work — not silently dropped.

See the module →
04

Unclaimed entitlement

“The threshold was crossed. Nobody raised the claim.”

Typical cost
0.3% – 1.1% of purchase spend
Benchmark
Best-in-class recover >98% of earned entitlement within one claim cycle.

How it closes: Agreement terms become executable rules on both sides of the trade. The accrual engine evaluates them nightly against real transactions and raises the claim — or the liability — itself.

See the module →
08

Deduction & dispute write-off

“It was cheaper to write it off than to fight it.”

Typical cost
0.2% – 0.9% of gross revenue
Benchmark
Strong programmes resolve >85% of deduction value without manual research.

How it closes: Deductions are matched to their authorising claim automatically; only genuine exceptions reach a human, so small balances stop being written off by default.

See the module →
09

Reporting latency

“By the time you saw the number, the quarter was over.”

Typical cost
1 – 2 quarters of decision lag
Benchmark
Leading programmes see channel sell-through within 5 business days of period end.

How it closes: Materialised snapshots make financial reads instant, so channel performance is a screen you open — not a pack you wait for.

See the module →
See all nine leak points →

Terminology

The words this industry uses

Sector-specific language, defined — because a chargeback in pharma and a ship-and-debit in semiconductor are the same transaction with different names.

Chargeback ↗
Your claim to a manufacturer for the difference between your acquisition cost and the contract price you were required to sell at.
GPO ↗
A group purchasing organisation that negotiates prices on behalf of member facilities you sell to.
Membership roster
The list of facilities eligible for a contract price on a given date — the most common reason a chargeback is rejected.
Rebill
Resubmitting a corrected chargeback after a rejection, at an administrative cost that often exceeds small lines.
Admin fee
The fee the GPO charges the manufacturer, reported on and reconciled alongside chargeback activity.
Open the full terminology library →

Programmes

What RevUpra runs for medical devices & pharma

  • Contract price and eligibility validated before invoicing
  • Chargeback generation with manufacturer-specific identifiers resolved
  • Rejection triage normalised across manufacturer reason codes
  • Roster ingestion with as-at-date eligibility history
  • Contract price file intake with effective-date enforcement

See this run against your own medical devices & pharma data.

The fastest way to size the opportunity is a diagnostic on one quarter of your real data — claims, purchases or sell-through. We will tell you what your actual rates are.

Book a demo Read the leak map